KalVista Pharmaceuticals, Ltd. Report issue

For profit Phase 2 Phase 3
Founded: Norton United Kingdom (2011)
Status: Acquired by Merck (2017)

Organization Overview

First Clinical Trial
2014
NCT02193113
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

KalVista Pharmaceuticals | KalVista Pharmaceuticals, Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: KalVista Pharmaceuticals, Ltd. (1) Acquired (1)

kvd900 (4 trials)

triamcinolone (kenalog) (1 trial)

Drugs in Phase 2 Trials (2)

kvd001 (2 trials)

kvd824 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angioedema (Phase 2)

Angioedemas, Hereditary (Phase 2)

Edema (Phase 2)

Hereditary Angioedema Types I and II (Phase 2)

Macular Edema (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 4